Splitting agent 'likely cause' of Fluvax events in children
MORE than two years after Fluvax caused a spike in febrile convulsions in children aged under five years, CSL today announced the preliminary results of its lengthy investigation.
The initial conclusion, presented today at the 13th National Immunisation Conference in Darwin, is that CSL’s method of influenza vaccine manufacture retains more virus components than that of other manufacturers.
The particular characteristics of the 2010 virus components elicited an excessive immune response in some children, triggering increased fever and related convulsions.
CSL uses taurodeoxycholate (TDOC